BSEM NASDAQ
BioStem Technologies, Inc.
1W: -34.1%
1M: -22.9%
3M: -25.4%
YTD: -30.4%
1Y: -45.3%
3Y: +11.4%
5Y: +110.0%
$2.73
-0.34 (-11.07%)
Weekly Expected Move ±16.0%
$2
$2
$3
$3
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (39)
BioStem Technologies prices $3M private placement
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
Biostem raises 2026 revenue outlook to $26M-$29M while targeting manufacturing transfer in H1 2027
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent
BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026
BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer
BioStem Technologies (OTCMKTS:BSEM) Shares Down 4.8% – Here’s What Happened
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
BioStem Technologies GAAP EPS of -$0.67, revenue of $10.1M
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026
BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference
BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference
BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research
BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research
BioStem Technologies, Inc. (BSEM) M&A Call Transcript
BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business
BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies (OTCMKTS:BSEM) Shares Down 0.8% – Time to Sell?
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
BioStem Technologies Expands Product Access in Medicaid